# Summary
Mounjaro causes greater loss of lean muscle mass compared to Ozempic, according to emerging research on these two GLP-1 drugs. Both medications suppress appetite and aid weight loss, but they work through different mechanisms. Mounjaro targets two hormones (GLP-1 and GIP), while Ozempic targets only GLP-1.
The dual-hormone approach in Mounjaro appears to accelerate muscle breakdown alongside fat loss. Studies show patients on Mounjaro lose more total weight, but a higher percentage comes from lean tissue rather than pure fat. This matters because muscle supports metabolism, strength, and bone health.
Ozempic users still lose lean mass, but at slower rates. The difference becomes pronounced at higher doses or with longer treatment duration.
Both drugs require pairing with adequate protein intake and resistance exercise to preserve muscle. Without these interventions, patients on either medication risk metabolic slowdown and weakness. The takeaway: drug choice alone doesn't determine body composition outcomes. Lifestyle factors remain the primary lever. Anyone considering GLP-1 therapy should consult their doctor about muscle preservation strategies specific to their chosen medication.